To test how Adam2 impacts not only efficacy of ACT but potentially also immune-checkpoint blockade (ICB), C57BL/6 mice bearing CTRL or Adam2 O/E LLC tumors were treated with PDL1 or CTLA4 blocking antibodies (Ab) once the tumor reached 100mm3. Here, ADAM2 is linked to neoplasm.